ClinicalTrials.gg
RecruitingNCT03978377CLARIFYUpdated Mar 25, 2025

Cardiopulmonary Toxicity of Thoracic Radiotherapy

An observational study in Oesophageal Cancer and Non Small Cell Lung Cancer, sponsored by University Medical Center Groningen. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by University Medical Center Groningen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2018; still recruiting 8 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
320
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Esophageal Neoplasms by University Medical Center Groningen — 8 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · University Medical Center Groningen.

Started
2018
with 1 other
Observational
7 of 16
5 open now
Registered
9th of 16
by date

Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, this one is one of 2 that started in 2018, is one of 7 observational ones, and was the 9th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

8 of the 16 studies in Esophageal Neoplasms by University Medical Center Groningen are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Esophageal Neoplasms by University Medical Center Groningen, or all of them as a file.
02

Study summary

Radiotherapy improves locoregional control and survival of thoracic tumour patients. However, the associated exposure of normal tissues, often leads to side effects and possibly even reduces survival. Indeed, there is growing evidence that overall survival after radiotherapy for lung and oesophageal cancer is related to the radiation dose to heart and lungs. This suggests that thoracic radiotherapy causes mortality, which is currently not recognized as radiation-induced toxicity. So the question arises how to explain this treatment-related mortality.

Interestingly, Ghobadi et al demonstrated in rats that thoracic irradiation can lead to pulmonary hypertension (PH). Histopathological analysis showed that radiation-induced PH closely resembles the pulmonary arterial hypertension (PAH) subtype. Moreover, in a clinical pilot study we confirmed early signs of PH including dose-dependent reductions in blood flow towards the lungs in radiotherapy patients.

In general PH significantly affects survival. Moreover, the PAH subtype is the most-rapidly progressive and lethal subtype. However, medical treatment can significantly slow down PAH progression, providing opportunities for secondary prevention. Yet, hard evidence that radiation-induced PH is a clinically relevant phenomenon in patients treated for thoracic tumours, is lacking.

Read the detailed description

In the present study, the incidence and time course of treatment-related changes in cardio-pulmonary physiology will be assessed using standard diagnostic tools such as echocardiography, cardiac MRI (CMR) and serum biomarkers and relate them to the radiation dose distribution. Such insight in the characteristics of this possible radiation-induced PH and contributing risk factors is essential to develop primary (radiation dose optimization) prevention strategies.

The general objective of this study is to test the hypothesis that pulmonary hypertension (PH) is a clinically relevant radiation-induced side effect of thoracic irradiation. If confirmed this allows us to take appropriate measures in patient care to improve quality of life in thoracic cancer patients.

To investigate this hypothesis, the following specific aims have been defined:

  • To assess the incidence and time course of PH in a prospective cohort study in patients treated with radiotherapy for lung or oesophageal cancer.
  • To characterize other changes in myocardial function and pulmonary arteries, and their function using cardiac MR.
  • To determine treatment-related risk factors, in particular radiation dose factors to the lungs and heart that could be used for future optimization strategies to minimize the risk of inducing PH in these patients.
  • To determine the clinical impact by correlating PH to patient-rated outcome measure (PROMs) and survival. Taken together this study will determine if radiation-induced pulmonary hypertension is a clinically relevant toxicity and will provide information required for future studies on its prevention and treatment. In addition, more insight will be obtained on other forms of cardiovascular damage and complications that may occur in these patients.
03

Conditions studied

  • Oesophageal Cancer
  • Non Small Cell Lung Cancer

Keywords

  • Radiotherapy
  • Pulmonary hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study focuses on two patient populations: 1) Patients with oesophageal cancer in the mid or distal oesophagus, who will be treated with radiotherapy with curative intent, with or without chemotherapy, with or without surgery.

  1. Patients with NSCLC stage IIA-III or NSCLC stage IV with limited brain metastases (treatable with surgery or stereotactic radiosurgery) or SCLC limited disease (stage I-IIIB), who will be treated with radiotherapy with curative intent, with or without chemotherapy.

Patients will be included in 3 participating centers:

  • University Medical Center Groningen, Groningen, The Netherlands
  • Beatson West of Scotland Cancer Centre /NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
  • Radboud UMC, Nijmegen, The Netherlands

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with oesophageal cancer in the mid or distal oesophagus and patients with NSCLC stage IIA-III or NSCLC stage IV with limited (treatable with surgery or stereotactic radiosurgery) or SCLC limited disease (stage I-IIIB)
  • Scheduled for external-beam radiotherapy with curative intention.
  • WHO 0-2.
  • Age >= 18 years
  • Written .

Exclusion criteria

Exclusion Criteria:

  • No heart failure in the last 2 months
  • No pulmonary embolism in the last 2 months
  • gold IV
  • >35
  • History of thoracic radiotherapy
  • Noncompliance with any of the inclusion criteria - For MRI part: Contra indications for MRI

For MRI part:

  • for MRI
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
320 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients with high risk of pulmonary hypertension

    High-risk pulmonary hypertension according to ESC/ERS classification

    Time frame: 1 year

Secondary outcomes

  1. Troponine T change

    Change in Troponine T concentration, between baseline and at 1 year

    Time frame: 1 year

  2. NTproBNP change

    Change in NTproBNP concentration, between baseline and at 1 year

    Time frame: 1 year

  3. Number of patients with intermediate risk of pulmonary hypertension

    Intermediate risk of pulmonary hypertension according to ESC/ERS classification

    Time frame: 1 year

  4. Cumulative incidence of other late cardiopulmonary toxicity, as classified by CTCAE4.0

    Cumulative incidence of other late cardiopulmonary toxicity, as classified by CTCAE4.0

    Time frame: 1 year

  5. EORTC quality of life questionnaire C30

    PROMs (EORTC QoL C30), including five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting),

    Time frame: 1 year

  6. EORTC quality of life questionnaire LC13

    PROMs (EORTC QoL LC13), including lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.

    Time frame: 1 year

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Apr 2026, 91 months after the start.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 91 months is above that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2019
First posted
Jun 7, 2019
StartActual
Sep 1, 2018
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2027
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03978377
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Sep 1, 2018
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Mar 25, 2025

Study contacts

CT Muijs, MD PhD
Contact
c.t.muijs@umcg.nl
00315036115179
P van Luijk, DR
Contact
p.van.luijk@umcg.nl
0031503611739

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion